JNK1 and AP-1 protein expression levels were significantly reduced in NASH model rats following treatment with ECYCD or polyenylphosphatidylcholine (JNK1: P < 0.01, versus the HFD group; AP-1: P < 0.05, versus the HFD group). The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatohepatitis.